ArticleHeliyon2024
From risk to resilience: Climate change risk, ESG investments engagement and Firm's value.
Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In line with Sustainable Development Goals, firms are increasingly incorporating Environmental, Social, and Governance (ESG) considerations in their investment strategies. The effect of firms' climate change risk (FCCR) on firms' Value (FV), and how such investment engagements moderate this effect, is a prominent subject of debate among scholars, investors, and policymakers. To examine these dynamics, we analyze a dataset of 1771 United States (US)-listed firms from 2006 to 2021 to quantify the effect of FCCR on FV. We use the generalized method of moments model to achieve our objectives. The major findings are summarized as follows: First, FCCR has a negative and significant effect on FV. Second, ESG investments positively and significantly influence FV. Third, ESG investments significantly moderate the FCCR-FV relationship. We confirm our estimations are robust under different estimations strategies. Finally, this article provides a fresh perspective on risk management with significant policy implications for investors, managers, and regulators in the US. We suggest that ESG investing is an important strategic catalyst for US firms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.